{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:00:39Z","timestamp":1794916839323,"version":"4.9.1"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"27","license":[{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,5]]},"abstract":"<jats:p>The current first-line treatment for atherosclerotic cardiovascular disease (ASCVD) involves the reduction of a patient\u2019s low-density lipoprotein cholesterol (LDL-C) levels through the use of lipid-lowering drugs. However, even when other risk factors such as hypertension and diabetes are effectively managed, there remains a residual cardiovascular risk in these patients despite achieving target LDL-C levels with statins and new lipid-lowering medications. This risk was previously believed to be associated with lipid components other than LDL, such as triglycerides. However, recent studies have unveiled the crucial role of remnant cholesterol (RC) in atherosclerosis, not just triglycerides. The metabolized product of triglyceride-rich lipoproteins is referred to as triglyceride-rich remnant lipoprotein particles, and its cholesterol component is known as RC. Numerous pieces of evidence from epidemiological investigations and genetic studies demonstrate that RC plays a significant role in predicting the incidence of ASCVD. As a novel marker for atherosclerosis prediction, when LDL-C is appropriately controlled, RC should be prioritized for attention and intervention among individuals at high risk of ASCVD. Therefore, reducing RC levels through the use of various lipid-lowering drugs may yield long-term benefits. Nevertheless, routine testing of RC in clinical practice remains controversial, necessitating further research on the treatment of elevated RC levels to evaluate the advantages of reducing RC in patients at high risk of ASCVD.<\/jats:p>","DOI":"10.1097\/md.0000000000038754","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T16:01:47Z","timestamp":1720195307000},"page":"e38754","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["A significant presence in atherosclerotic cardiovascular disease: Remnant cholesterol: A review"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8166-0073","authenticated-orcid":false,"given":"Li","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Cardiology, Quanzhou Traditional Chinese Medicine Hospital, Quanzhou, Fujian Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingmei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Quanzhou First Hospital, Quanzhou, Fujian Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Quanzhou Traditional Chinese Medicine Hospital, Quanzhou, Fujian Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Puning People\u2019s Hospital, Jieyang City, Guangdong Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260109","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.jacc.2021.08.051","article-title":"New therapies for lowering triglyceride-rich lipoproteins: JACC focus seminar 3\/4.","volume":"78","author":"Rosenson","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1161\/CIRCULATIONAHA.121.057807","article-title":"Apolipoprotein B, residual cardiovascular risk after acute coronary syndrome, and effects of alirocumab.","volume":"146","author":"Hagstr\u00f6m","year":"2022","journal-title":"Circulation"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1177\/2047487319899622","article-title":"Beyond LDL-C levels, does remnant cholesterol estimation matter?","volume":"27","author":"Pirillo","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.","volume":"2","author":"Hegele","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease.","volume":"61","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11883-022-00994-z","article-title":"Remnants, LDL, and the quantification of lipoprotein-associated risk in atherosclerotic cardiovascular disease.","volume":"24","author":"Packard","year":"2022","journal-title":"Curr Atheroscler Rep"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/jch.14384","article-title":"Association between remnant cholesterol and arterial stiffness: a secondary analysis based on a cross-sectional study.","volume":"24","author":"Wang","year":"2022","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehs431","article-title":"Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction.","volume":"34","author":"J\u00f8rgensen","year":"2013","journal-title":"Eur Heart J"},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1210\/er.2018-00184","article-title":"The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk.","volume":"40","author":"Sandesara","year":"2019","journal-title":"Endocr Rev"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1373\/jalm.2017.024919","article-title":"Development of a novel homogeneous assay for remnant lipoprotein particle cholesterol.","volume":"3","author":"Hirao","year":"2018","journal-title":"J Appl Lab Med"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society.","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"R13-20260109","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/clinchem\/hvaa296","article-title":"Triglyceride-rich lipoprotein remnants and cardiovascular disease.","volume":"67","author":"Duran","year":"2021","journal-title":"Clin Chem"},{"key":"R14-20260109","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2337\/dbi19-0007","article-title":"Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease.","volume":"69","author":"Chait","year":"2020","journal-title":"Diabetes"},{"key":"R15-20260109","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1093\/eurheartj\/ehab293","article-title":"Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction.","volume":"42","author":"Varbo","year":"2021","journal-title":"Eur Heart J"},{"key":"R16-20260109","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12933-020-01076-7","article-title":"The longitudinal association of remnant cholesterol with cardiovascular outcomes in patients with diabetes and pre-diabetes.","volume":"19","author":"Cao","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"R17-20260109","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1373\/clinchem.2014.234146","article-title":"Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population.","volume":"61","author":"Varbo","year":"2015","journal-title":"Clin Chem"},{"key":"R18-20260109","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1373\/clinchem.2015.253757","article-title":"Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5414 patients with ischemic heart disease.","volume":"62","author":"Jepsen","year":"2016","journal-title":"Clin Chem"},{"key":"R19-20260109","doi-asserted-by":"crossref","first-page":"95","DOI":"10.5551\/jat.RV16003","article-title":"Postprandial hyperlipidemia and remnant lipoproteins.","volume":"24","author":"Masuda","year":"2017","journal-title":"J Atheroscler Thromb"},{"key":"R20-20260109","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jacl.2015.09.006","article-title":"Deficient serum 25-hydroxyvitamin D is associated with an atherogenic lipid profile: the Very Large Database of Lipids (VLDL-3) study.","volume":"10","author":"Lupton","year":"2016","journal-title":"J Clin Lipidol"},{"key":"R21-20260109","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/eurheartj\/ehac822","article-title":"Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality.","volume":"44","author":"Wadstr\u00f6m","year":"2023","journal-title":"Eur Heart J"},{"key":"R22-20260109","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"R23-20260109","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1001\/jama.2013.280532","article-title":"Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile.","volume":"310","author":"Martin","year":"2013","journal-title":"JAMA"},{"key":"R24-20260109","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1016\/j.jacc.2020.10.008","article-title":"Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease.","volume":"76","author":"Casta\u00f1er","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R25-20260109","doi-asserted-by":"crossref","first-page":"756057","DOI":"10.3389\/fcvm.2021.756057","article-title":"Clinical significance of intermediate-density lipoprotein cholesterol determination as a predictor for coronary heart disease risk in middle-aged men.","volume":"8","author":"Yoshida","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"R26-20260109","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1253\/circj.CJ-14-0380","article-title":"High remnant lipoprotein predicts recurrent cardiovascular events on statin treatment after acute coronary syndrome.","volume":"78","author":"Nguyen","year":"2014","journal-title":"Circ J"},{"key":"R27-20260109","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12933-022-01667-6","article-title":"Remnant cholesterol and the risk of cardiovascular disease in type 2 diabetes: a nationwide longitudinal cohort study.","volume":"21","author":"Huh","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"R28-20260109","doi-asserted-by":"crossref","first-page":"e002765","DOI":"10.1161\/JAHA.115.002765","article-title":"Remnant lipoprotein cholesterol and incident coronary heart disease: the Jackson heart and framingham offspring cohort studies.","volume":"5","author":"Joshi","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"R29-20260109","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1093\/eurheartj\/ehab432","article-title":"Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study.","volume":"42","author":"Quispe","year":"2021","journal-title":"Eur Heart J"},{"key":"R30-20260109","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3390\/metabo12100898","article-title":"The level of remnant cholesterol and implications for lipid-lowering strategy in hospitalized patients with acute coronary syndrome in China: findings from the improving care for cardiovascular disease in China-acute coronary syndrome project.","volume":"12","author":"Yang","year":"2022","journal-title":"Metabolites"},{"key":"R31-20260109","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/joim.13059","article-title":"Contribution of remnant cholesterol to cardiovascular risk.","volume":"288","author":"Langsted","year":"2020","journal-title":"J Intern Med"},{"key":"R32-20260109","doi-asserted-by":"crossref","first-page":"913869","DOI":"10.3389\/fcvm.2022.913869","article-title":"Remnant cholesterol and atherosclerotic cardiovascular disease: metabolism, mechanism, evidence, and treatment.","volume":"9","author":"Wang","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"R33-20260109","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrcardio.2018.3","article-title":"Advances in lipid-lowering therapy through gene-silencing technologies.","volume":"15","author":"Nordestgaard","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"R34-20260109","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.cca.2018.04.007","article-title":"Remnant-like particles and coronary artery disease in familial hypercholesterolemia.","volume":"482","author":"Tada","year":"2018","journal-title":"Clin Chim Acta"},{"key":"R35-20260109","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 deficiency and protection against coronary artery disease.","volume":"69","author":"Stitziel","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R36-20260109","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2017.0972","article-title":"Association of rare and common variation in the lipoprotein lipase gene with coronary artery disease.","volume":"317","author":"Khera","year":"2017","journal-title":"JAMA"},{"key":"R37-20260109","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41590-019-0548-1","article-title":"Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation.","volume":"21","author":"Zewinger","year":"2020","journal-title":"Nat Immunol"},{"key":"R38-20260109","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.jacc.2018.08.1043","article-title":"Inflammation, immunity, and infection in atherothrombosis: JACC review topic of the week.","volume":"72","author":"Libby","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R39-20260109","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1016\/j.jacc.2020.10.029","article-title":"Remnant cholesterol and atherosclerotic cardiovascular disease risk.","volume":"76","author":"Burnett","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R40-20260109","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/MOL.0000000000000429","article-title":"Remnant lipoproteins.","volume":"28","author":"Varbo","year":"2017","journal-title":"Curr Opin Lipidol"},{"key":"R41-20260109","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/j.jacc.2014.09.042","article-title":"Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease.","volume":"64","author":"Rosenson","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R42-20260109","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/joim.12605","article-title":"Arterial ageing: from endothelial dysfunction to vascular calcification.","volume":"281","author":"Tesauro","year":"2017","journal-title":"J Intern Med"},{"key":"R43-20260109","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2147\/VHRM.S104369","article-title":"Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease.","volume":"12","author":"Toth","year":"2016","journal-title":"Vasc Health Risk Manag"},{"key":"R44-20260109","doi-asserted-by":"crossref","first-page":"117141","DOI":"10.1016\/j.atherosclerosis.2023.05.010","article-title":"Dual elevated remnant cholesterol and C-reactive protein in myocardial infarction, atherosclerotic cardiovascular disease, and mortality.","volume":"379","author":"Doi","year":"2023","journal-title":"Atherosclerosis"},{"key":"R45-20260109","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrcardio.2017.31","article-title":"Hypertriglyceridaemia and risk of coronary artery disease.","volume":"14","author":"Reiner","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"R46-20260109","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.atherosclerosis.2019.02.019","article-title":"Remnant cholesterol and coronary atherosclerotic plaque burden assessed by computed tomography coronary angiography.","volume":"284","author":"Lin","year":"2019","journal-title":"Atherosclerosis"},{"key":"R47-20260109","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology.","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"issue":"6 Suppl 1","key":"R48-20260109","first-page":"e3","article-title":"[2021 ESC Guidelines on cardiovascular disease prevention in clinical practice].","volume":"23","author":"Visseren","year":"2022","journal-title":"G Ital Cardiol (Rome)"},{"key":"R49-20260109","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.clinthera.2016.02.001","article-title":"Pitavastatin 4\u2009mg provides significantly greater reduction in remnant lipoprotein cholesterol compared with pravastatin 40 mg: results from the short-term phase IV PREVAIL US trial in patients with primary hyperlipidemia or mixed dyslipidemia.","volume":"38","author":"Miller","year":"2016","journal-title":"Clin Ther"},{"key":"R50-20260109","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.atherosclerosis.2016.01.028","article-title":"Fenofibrate, HDL, and cardiovascular disease in type-2 diabetes: the DAIS trial.","volume":"247","author":"Tsunoda","year":"2016","journal-title":"Atherosclerosis"},{"key":"R51-20260109","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus.","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"R52-20260109","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamacardio.2017.5205","article-title":"Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals.","volume":"3","author":"Aung","year":"2018","journal-title":"JAMA Cardiol"},{"key":"R53-20260109","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"R54-20260109","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12944-016-0197-4","article-title":"Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo.","volume":"15","author":"Toth","year":"2016","journal-title":"Lipids Health Dis"},{"key":"R55-20260109","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1080\/14656566.2020.1787380","article-title":"Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia.","volume":"21","author":"D\u2019Erasmo","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"R56-20260109","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.jacc.2013.07.023","article-title":"Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL\/High Triglycerides and Impact on Global Health Outcomes).","volume":"62","author":"Guyton","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R57-20260109","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","article-title":"Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.","volume":"112","author":"Graham","year":"2013","journal-title":"Circ Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038754","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:04:58Z","timestamp":1767967498000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,5]]},"references-count":57,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000038754","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,5]]}}}